Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XBMIV
ADC Name
AbA_D265C_LALA_H435A-AM1
Synonyms
AbA_D265C_LALA_H435A-AM1
   Click to Show/Hide
Organization
Vor Biopharma Inec.
Drug Status
Investigative
Antibody Name
undisclosed
Antigen Name
Receptor-type tyrosine-protein phosphatase C (PTPRC)
  Antigen Info 
Payload Name
US12209180B2 AM1
  Payload Info 
Linker Name
Undisclosed
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
Click To Hide/Show 3 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 122 ug/mL/mg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Maximum Observed Concentration (Cmax) 18.7 ug/mL/mg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Time to Maximum Concentration (Tmax) 0.083 hr
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Distribution
Click To Hide/Show 2 Distribution Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 122 ug/mL/mg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Volume of Distribution (Vd) 44.2 mL/kg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Metabolism
Click To Hide/Show 1 Metabolism Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 122 ug/mL/mg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Excretion
Click To Hide/Show 3 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 122 ug/mL/mg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Elimination Half-Life (t1/2) 3.79 hr
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
Clearance (CL) 8.46 mL/hr/kg
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicates that the ADCs were serum stable in vivo in NHPs.
 [1]
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (IC50) 
0.012
nM
CVCL_0140
Normal
Half Maximal inhibitory Concentration (IC50) 
0.023
nM
CVCL_0140
Normal
Half Maximal inhibitory Concentration (IC50) 
0.36
nM
CVCL_1650
B acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (IC50) 
0.372
nM
Undisclosed
Bone marrow hematopoietic stem cells
Half Maximal inhibitory Concentration (IC50) 
0.71
nM
CVCL_1650
B acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (IC50) 
1.1
nM
CVCL_0065
T acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (IC50) 
1.365
nM
CVCL_2196
Adult acute myeloid leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 0.012 nM Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description
In vitro PBMC killing assays: ADCs conjugated to AM1
In Vitro Model Normal PBMC cells CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 0.023 nM Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description
In vitro PBMC killing assays: ADCs conjugated to AM1
In Vitro Model Normal PBMC cells CVCL_0140
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 0.36 nM Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description
In vitro cell line killing assays
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 0.372 nM Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description
In vitro BM HSC killing assay: ADCs conjugated to AM1 or PBD
In Vitro Model Bone marrow hematopoietic stem cells BM HSC cells (CD34+CD90+) Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 0.71 nM Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description
In vitro cell killing assays: ADCs conjugated to AM1, AM2, or PBD
In Vitro Model B acute lymphoblastic leukemia Reh cells CVCL_1650
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 1.1 nM Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description
In vitro cell line killing assays
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50) 1.365 nM Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description
In vitro cell line killing assays
In Vitro Model Adult acute myeloid leukemia SKNO-1 cells CVCL_2196
References
Ref 1 Anti-CD45 antibodies and conjugates thereof